Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BW-20507
- Development stage
- Phase 2
- Lead developer
- Shanghai Argo Biopharmaceutical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
**BW-20507** is a double-stranded, N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) specifically designed to target the S region of hepatitis B virus (HBV) messenger RNA in hepatocytes using hepatocyte-specific delivery via asialoglycoprotein receptor-mediated uptake. Developed by Argo Biopharma, BW-20507 inhibits several HBV mRNA transcripts, broadly suppressing expression of viral antigens (except HBx) and resulting in a marked reduction of HBsAg and HBV DNA levels in both nucleos(t)ide (NUC)-experienced and NUC-naïve chronic hepatitis B (CHB) patients. Phase 1/2a studies show significant, dose-dependent reductions in HBsAg (up to -3.2 log₁₀ IU/mL for higher-dose cohorts), with some patients achieving HBsAg loss, as well as potent antiviral activity and a favorable safety profile. The drug has received Breakthrough Therapy Designation in China based on early clinical data and is being advanced into Phase 2b clinical development as monotherapy and in combination with pegylated interferon for CHB.
- Other names
- HBV-siRNA
02
Targets
HBV (Hepatitis B virus)
Beyond the preview
Go deeper on BW-20507.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BW-20507.